Corcept Therapeutics Inc's Comment on Supply Chain
Suppliers and their firms are subject to FDA inspections to ensure compliance with current Good Manufacturing Practices (cGMP). Violations may result in enforcement actions that impact operations and product distribution. After product approval, the FDA may require additional testing and monitoring; identification of issues can lead to recalls or distribution restrictions. Changes in safety data or regulatory requirements may necessitate updates to labeling or implementation of risk management measures. The Hatch-Waxman amendments establish procedures for abbreviated new drug applications (ANDA) for generic drugs, which require data on active ingredients, formulation, and manufacturing processes but generally do not require clinical data. Bioequivalence studies are necessary to demonstrate similarity to reference drugs. FDA approval is based on criteria including safety, effectiveness, and bioequivalence.
Corcept Therapeutics Inc's Comment on Supply Chain
Suppliers and their firms are subject to FDA inspections to ensure compliance with current Good Manufacturing Practices (cGMP). Violations may result in enforcement actions that impact operations and product distribution. After product approval, the FDA may require additional testing and monitoring; identification of issues can lead to recalls or distribution restrictions. Changes in safety data or regulatory requirements may necessitate updates to labeling or implementation of risk management measures. The Hatch-Waxman amendments establish procedures for abbreviated new drug applications (ANDA) for generic drugs, which require data on active ingredients, formulation, and manufacturing processes but generally do not require clinical data. Bioequivalence studies are necessary to demonstrate similarity to reference drugs. FDA approval is based on criteria including safety, effectiveness, and bioequivalence.
Sources:
Corcept Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Corcept Therapeutics Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
